All Posts Tagged With: "ABT"
(ABT) Abbott Labs Boosts Immunology Pipeline
Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061.
The Candidate: BT-061
The...
(MDT) Medical Devices Stock Outlook – June 2011 – Industry Outlook
A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of...
(USA) Company News for June 20, 2011 – Corporate Summary
• Research In Motion Limited (NASDAQ:RIMM) reported first quarter earnings per share of $1.33. While this is marginally higher than the Zacks Consensus EPS Estimate of $1.32 per share, revenue numbers missed expectations...
(ABT) Abbott Labs’ Bardoxolone in Phase III Trials
Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with...
(JNJ) Johnson & Johnson to Discontinue Cypher Stent
Cordis Corporation, a Johnson & Johnson (JNJ) company, recently announced that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year end.
The company...
(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook
Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between...
(MYL) Mylan Launches New Generic Pharmaceuticals
Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development...
(VIVO) FDA OKs Meridian C. Difficile Test
Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier...
(ABT) Abbott Laboratories Earns FDA Approval of AndroGel
Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero...
(DXCM) DexCom Misses Analyst Estimates
DexCom (DXCM), a prominent player in the glucose monitoring market, reported first-quarter fiscal 2011 loss per share of 19 cents, a penny higher than the Zacks Consensus Estimate while sharply less than...
(HOLX) Hologic Earnings Report Shows Strong Growth
Hologic (HOLX) reported an adjusted EPS of 30 cents during the second quarter of fiscal 2011, surpassing the Zacks Consensus Estimate by 2 cents and a penny above the year-ago quarter. Revenues were $438.7...
(AMGN) Amgen Beats First Quarter Estimates – Maintains Outlook
Amgen (AMGN) reported first quarter earnings per share of $1.32, 3 cents above the Zacks Consensus Estimate of $1.29 and 3.1% above year-ago earnings. Higher revenues, a lower tax rate and lower share count...
(INTC) Staying Power of the Earnings Growth Momentum
Wednesday, April 20, 2011
With the earnings season getting into full gear, I am increasingly getting more optimistic about the staying power of the earnings growth momentum. My favorable takeaway does not reflect the stand-out results from tech bellwethers like Intel...
(ABT) Abbott Labs First Quarter 2011 Earnings Preview
Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing...
(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing
Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on...
(BSX) Boston Scientific Presents Positive Stent Results
Boston Scientific (BSX) presented an analysis on data derived from two trials – Perseus and Taxus Atlas at the American College of Cardiology annual conference. It was observed that the...
(LLY) Eli Lilly’s Axiron Testosterone Deficiency Drug Launched in the U.S.
Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement...
(MDT) Medical Devices Industry Outlook – April 2011 – Industry Outlook
Last year was challenging for medical device companies given the exigent economic conditions and an uncertain healthcare environment. The MedTech industry was hit by several macro headwinds in 2010 including price/volume and utilization pressure and a more restrictive regulatory...
(JNJ) Japan Quake Impact on Medical Technology
Tremors triggering a quake, which struck about 250 miles north of Tokyo, followed by a colossal Tsunami, wreaked havoc on the people of the “Land of the Rising Sun” on March 11, resulting in massive carnage and destruction.
The catastrophe,...
(JNJ) Pharmaceutical Industry Outlook – March 2011 – Industry Outlook
The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance...
(OREX) Orexigen Therapeutics Gets Severe Setback from US Food and Drug Administration
Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the US Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present...
(ABT) Company News for January 20, 2011 – Corporate Summary
• Share prices of tech major IBM (NYSE:IBM) rose by 3.35% after the company posted excellent earnings figure on Tuesday night
• Adtran Inc (NASDAQ:ADTN) increased...
(LLY) Eli Lilly and Company Gets FDA Approval of Axiron
Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. The FDA approved Axiron for use as a replacement therapy...
(DXCM) DexCom Earnings Report Meets The Street but Sales Miss
DexCom (DXCM) reported third-quarter 2010 loss per share of 23 cents, matching the Zacks Consensus Estimate and improving from the year-ago loss of 29 cents.
Revenues
Total...
(AUXL) Auxilium Pharmaceuticals Reports Narrower Loss
Auxilium Pharmaceuticals, Inc. (AUXL) reported a third quarter loss of 27 cents per share, narrower than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 35 cents. Higher revenues...
(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook
With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant...
(SYK) Stryker Agrees to Aquire Boston Scientific Unit for $1.5 Billion
Orthopedic devices giant Stryker Corp (SYK) has forged a definitive agreement to acquire medical devices major Boston Scientific’s (BSX)...
(BSX) Boston Scientific Quarterly Earnings Double Estimates
Boston Scientific (BSX) reported adjusted EPS of 12 cents, far ahead of the Zacks Consensus Estimate of 6 cents. However, earnings were flat on a year-over-year basis. Adjusted EPS includes intangible asset...
(ABT) Company News for October 20, 2010 – Corporate Summary
• BlackRock (NYSE:BLK) topped sales and earnings projections with third quarter results of $2.75, $0.30 above Zacks estimates on revenues of $2.09 billion, up 83.5% and above Zacks estimates of $2 billion
• Morgan Stanley (NYSE:MS) reported earnings of $0.23 ex-items,...
(ABT) Abbott Labs Removes Obesity Drug Meridia From Market
Abbott Labs (ABT) recently announced its intention to pull obesity drug Meridia from the US market. Abbott Labs’ decision was based on a request made by the US Food and Drug Administration (FDA).
The...